证券代码：688799 证券简称：华纳药厂 公告编号：2025-096 湖南华纳大药厂股份有限公司 自愿披露关于获得药品注册证书的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2、剂型：注射剂 3、规格：4ml：8mg 4、申请事项：药品注册（境内生产） 5、注册分类：化学药品 3 类 6、受理号：CYHS2402087 7、药品批准文号：国药准字 H20256386 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的重酒石酸去甲肾上腺素注射液《药品注册证书》，现将相关 情况公告如下： 一、药品相关信息 1、药品名称：重酒石酸去甲肾上腺素注射液 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范 要求方可生产销售。 二、药品的相关情况 重酒石酸去甲肾上腺素注射液用于急性低血压状态的血压恢复；也可用于心 跳骤停的辅助治疗和心跳 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has received approval from the National Medical Products Administration for the registration certificate of the drug "Rocuronium Bromide Injection," which is used for the treatment of acute hypotensive states and as an auxiliary treatment for cardiac arrest [1] Group 1 - The drug is indicated for restoring blood pressure in acute hypotensive states [1] - It can also be used as an auxiliary treatment for cardiac arrest and to maintain blood pressure after resuscitation [1] - The product serves as an auxiliary treatment for shock due to insufficient blood volume, helping to temporarily maintain cerebral and coronary perfusion until volume resuscitation takes effect [1]

特此公告。 湖南华纳大药厂股份有限公司董事会 2025 年 12 月 25 日 证券代码：688799 证券简称：华纳药厂 公告编号：2025-095 湖南华纳大药厂股份有限公司 关于选举第四届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南华纳大药厂股份有限公司（以下简称"公司"）于 2025 年 12 月 10 日召 开了第四届董事会第四次会议和第四届监事会第四次会议，审议通过了《关于变 更注册资本、取消监事会、调整董事会人数、修订<公司章程>并办理工商变更 登记的议案》。根据修订后的《公司章程》规定，公司董事会由 9 名董事组成， 其中职工代表董事 1 名，由公司职工代表大会选举产生。 公司于 2025 年 12 月 24 日召开 2025 年第一次职工代表大会，同意选举皮士 卿先生担任公司第四届董事会职工代表董事（简历详见附件），任期自公司 2025 年第二次临时股东大会审议通过《关于变更注册资本、取消监事会、调整董事会 人数、修订<公司章程>并办理工商变更登记的议案》之日起至公司第四 ...

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has received approval from the National Medical Products Administration for the registration certificate of Isoproterenol Hydrochloride Injection, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - The Isoproterenol Hydrochloride Injection is indicated for the treatment of cardiogenic or infectious shock, complete atrioventricular block, and cardiac arrest [1] - The product has been classified as a Category 3 chemical drug under the new registration classification, which is equivalent to passing the consistency evaluation [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has received approval from the National Medical Products Administration for the registration of Isoproterenol Hydrochloride Injection, which is intended for treating cardiogenic or infectious shock and complete atrioventricular block, as well as cardiac arrest [1] Group 1: Product Approval - The drug name is Isoproterenol Hydrochloride Injection, with registration numbers Guoyao Zhunzi H20256315 and Guoyao Zhunzi H20256316 [1] - The injection is classified as a Category 3 chemical drug under the new registration classification, which is equivalent to passing the consistency evaluation [1] Group 2: Impact on Company - The approval of Isoproterenol Hydrochloride Injection enriches the company's formulation product variety and positively contributes to optimizing the company's product structure [1] - The acquisition of the drug registration certificate is not expected to have a significant impact on the company's recent performance [1]

证券代码：688799 证券简称：华纳药厂 公告编号：2025-094 一、药品相关信息 1、药品名称：盐酸异丙肾上腺素注射液 2、剂型：注射剂 湖南华纳大药厂股份有限公司 自愿披露关于获得药品注册证书的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的盐酸异丙肾上腺素注射液《药品注册证书》，现将相关情况 公告如下： 3、规格：1ml:0.2mg、5ml:1mg 4、申请事项：药品注册（境内生产） 5、注册分类：化学药品 3 类 6、受理号：CYHS2401533、CYHS2401534 7、药品批准文号：国药准字 H20256315、国药准字 H20256316 8、上市许可持有人：湖南华纳大药厂股份有限公司 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范 要求方可生产销售 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has received approval from the National Medical Products Administration for the registration of Isoproterenol Hydrochloride Injection, which is intended for treating cardiogenic or infectious shock and complete atrioventricular block, as well as cardiac arrest [1] Group 1 - The drug is classified as a Class 3 chemical drug under the new registration category and is considered to have passed the consistency evaluation [1] - The approval of Isoproterenol Hydrochloride Injection enriches the company's formulation product variety and positively impacts the optimization of the company's product structure [1] - The acquisition of the drug registration certificate is not expected to have a significant impact on the company's recent performance [1]

Core Viewpoint - Warner Pharmaceuticals (688799) has received approval from the National Medical Products Administration for the registration certificate of Isoproterenol Hydrochloride Injection, which is used for treating cardiogenic or infectious shock, complete atrioventricular block, and cardiac arrest [1] Group 1 - The approval of Isoproterenol Hydrochloride Injection marks a significant milestone for the company in expanding its product offerings in critical care [1] - The drug is indicated for serious medical conditions, potentially increasing its market demand and relevance in emergency medicine [1] - This development may enhance the company's competitive position within the pharmaceutical industry, particularly in the cardiovascular treatment segment [1]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]